Delayed, transient and self-resolving neutropenia following COVID-19 pneumonia.
Victoria Marie Ferreira MankJeffrey MankJenie OgleJefferson RobertsPublished in: BMJ case reports (2021)
A novel coronaravirus, identified as SARS-CoV-2, spread throughout the world in 2020. The COVID-19 pandemic has led to many discoveries and clinical manifestations. A young patient is presented with new, self-resolving neutropenia presenting weeks after a prolonged hospital stay for COVID-19 pneumonia. Workup included analysis for underlying infection, nutritional abnormalities, malignancy, medication and toxin exposure, all of which were negative. From 2020 to the present, few reports have described neutropenia associated with a recent COVID-19 infection. In particular, no reports have described a delayed presentation of neutropenia. The authors would like to propose that the significant inflammatory response associated with COVID-19 is likely what led to this patient's postviral neutropenia. Furthermore, in young healthy patients, bone marrow biopsy may be deferred and a watchful-waiting approach may be taken to assess for neutropenia resolution.
Keyphrases
- sars cov
- chemotherapy induced
- coronavirus disease
- case report
- inflammatory response
- bone marrow
- respiratory syndrome coronavirus
- adverse drug
- end stage renal disease
- healthcare
- newly diagnosed
- escherichia coli
- chronic kidney disease
- ejection fraction
- mesenchymal stem cells
- prognostic factors
- emergency department
- peritoneal dialysis
- extracorporeal membrane oxygenation
- single molecule
- drug induced
- acute care
- ultrasound guided